AI-generated research brief — verify at source
Fulvestrant Extends Progression-Free Survival Nearly Twofold Over Capecitabine as Maintenance in HR+/HER2− Metastatic Breast Cancer
In a randomized phase 3 trial, fulvestrant maintenance therapy nearly doubled median progression-free survival compared with capecitabine in hormone receptor-positive, HER2-negative metastatic breast cancer patients following first-line chemotherapy (17.3 months versus 9.0 months; about 37% lower risk of progression or death, HR 0.63, 95% CI 0.47–0.99; p = 0.003). The benefit was accompanied by a markedly more favorable tolerability profile, strengthening the case for a chemotherapy-free maintenance approach in this setting.
What Was Studied
The trial investigated whether fulvestrant, an endocrine therapy, could outperform capecitabine, an oral chemotherapy agent, when used as maintenance treatment after first-line chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The primary outcome was investigator-assessed progression-free survival, a critical measure in the metastatic setting where prolonging remission without excessive toxicity is a central clinical goal.
How It Was Studied
The FAMILY trial was a multicenter, open-label, randomized phase 3 study conducted across 22 hospitals in mainland China. It enrolled 210 patients with hormone receptor-positive, HER2-negative metastatic breast cancer who had achieved either an objective response or disease control following first-line chemotherapy — a population in which the question of how best to sustain that benefit is particularly consequential. Participants were randomly assigned in equal numbers, with 105 allocated to each treatment arm. The median follow-up at the data cutoff of March 1, 2025, was 33.6 months, with individual follow-up ranging from 1.5 to 81.1 months, providing a reasonably mature dataset for the primary endpoint assessment.
What Was Observed
- Progression-free survival favored fulvestrant substantially. Median PFS was 17.3 months (95% CI 12.7–23.3) in the fulvestrant group versus 9.0 months (95% CI 7.5–14.3) in the capecitabine group — representing approximately 37% lower risk of progression or death with fulvestrant (HR 0.63, 95% CI 0.47–0.99; p = 0.003). The 8.3-month absolute difference in median PFS is clinically meaningful in the metastatic setting.
- Serious toxicity was markedly lower with fulvestrant. Grade 3 or higher adverse events occurred in only 2.9% of patients receiving fulvestrant, compared with 10.5% in the capecitabine group — more than a threefold difference in high-grade toxicity burden.
- Treatment discontinuation due to adverse events was absent in the fulvestrant arm. No patients discontinued fulvestrant because of toxicity, whereas 7.6% of capecitabine-treated patients stopped therapy for this reason, indicating a clinically important difference in tolerability and treatment sustainability.
- Overall survival data remain immature. Survival outcomes had not reached sufficient maturity by the data cutoff date and were therefore not reported, leaving the ultimate impact on longevity unresolved at this stage of follow-up.
Why This Matters
Maintenance therapy following first-line chemotherapy is a recognized priority in hormone receptor-positive, HER2-negative metastatic breast cancer, yet the optimal strategy remains an open question. This trial directly addresses that gap by demonstrating that switching to endocrine-based maintenance with fulvestrant, rather than continuing chemotherapy in the form of capecitabine, produces both a longer remission and substantially less toxicity. The combination of improved disease control and a cleaner safety profile supports a meaningful shift in how maintenance sequencing might be approached in this patient population.
How to Read This Result
While this well-designed phase 3 trial provides encouraging evidence favoring fulvestrant maintenance, the upper bound of the hazard ratio confidence interval nearly reaches 1.0 (95% CI 0.47–0.99), overall survival data remain immature, and the open-label design introduces the possibility of investigator bias in PFS assessment, all of which warrant measured interpretation pending longer-term follow-up.
Limitations
Overall survival data had not yet reached maturity at the time of data cutoff, meaning the most definitive efficacy endpoint remains unanswered. The open-label design — in which both patients and investigators were aware of treatment allocation — may have introduced assessment bias in the investigator-reported PFS endpoint. The trial was conducted exclusively at sites in mainland China, which may limit how broadly the findings can be generalized to other populations or healthcare settings with different patient characteristics or treatment practices.